In a previous case report, a Chinese, 44‑year‑old, female non‑smoker with stage IV NSCLC harbouring SPECC1L‑ALK fusion was treated with crizotinib ± bevacizumab for 23 months (from October 2017 to September 2019) and second‑generation ALK inhibitor iruplinalkib for 2.5 months (from October 2019 to January 2020). The present study is an updated case report of subsequent follow‑up of this patient....Intracranial complete response was achieved nearly 5 months after iruplinalkib treatment initiation. Systemic and intracranial responses continued as of cut‑off date (February 2023). The progression‑free survival reached 39.3 months...